Shares of Quidel Co. (NASDAQ:QDEL) have earned a consensus rating of “Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $71.40.

A number of equities research analysts have commented on QDEL shares. ValuEngine upgraded Quidel from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Zacks Investment Research cut Quidel from a “buy” rating to a “hold” rating in a research note on Saturday, February 16th. Barclays increased their price target on Quidel from $74.00 to $77.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. BidaskClub upgraded Quidel from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 4th. Finally, Craig Hallum increased their price target on Quidel from $51.00 to $63.00 and gave the company a “hold” rating in a research note on Thursday, February 14th.

In related news, CEO Douglas C. Bryant sold 31,443 shares of Quidel stock in a transaction that occurred on Tuesday, February 26th. The stock was sold at an average price of $65.72, for a total transaction of $2,066,433.96. Following the completion of the transaction, the chief executive officer now directly owns 322,006 shares in the company, valued at $21,162,234.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Douglas C. Bryant sold 25,250 shares of Quidel stock in a transaction that occurred on Tuesday, January 29th. The shares were sold at an average price of $55.09, for a total value of $1,391,022.50. Following the transaction, the chief executive officer now owns 319,563 shares of the company’s stock, valued at $17,604,725.67. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 282,848 shares of company stock valued at $18,490,522. Company insiders own 16.70% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Quidel by 4.7% in the third quarter. BlackRock Inc. now owns 2,291,654 shares of the company’s stock valued at $149,348,000 after acquiring an additional 102,724 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Quidel in the 3rd quarter worth about $347,000. Jane Street Group LLC purchased a new position in Quidel in the 3rd quarter worth about $229,000. Man Group plc raised its position in Quidel by 191.7% in the 3rd quarter. Man Group plc now owns 75,641 shares of the company’s stock worth $4,929,000 after buying an additional 49,706 shares during the last quarter. Finally, Verition Fund Management LLC raised its position in Quidel by 41.3% in the 3rd quarter. Verition Fund Management LLC now owns 7,728 shares of the company’s stock worth $504,000 after buying an additional 2,260 shares during the last quarter. Institutional investors own 92.88% of the company’s stock.

QDEL stock traded down $0.36 during trading on Thursday, reaching $59.48. 193,774 shares of the company traded hands, compared to its average volume of 162,248. Quidel has a 12 month low of $44.27 and a 12 month high of $77.63. The company has a market cap of $2.37 billion, a P/E ratio of 21.09, a PEG ratio of 0.85 and a beta of 1.37. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.21 and a quick ratio of 0.79.

Quidel (NASDAQ:QDEL) last released its quarterly earnings results on Wednesday, February 13th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.21. Quidel had a return on equity of 31.73% and a net margin of 14.20%. The company had revenue of $132.59 million during the quarter, compared to analysts’ expectations of $132.26 million. During the same period last year, the business posted $0.56 earnings per share. The firm’s revenue was up 15.4% compared to the same quarter last year. On average, analysts anticipate that Quidel will post 2.79 EPS for the current year.

Quidel Company Profile

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.

Recommended Story: Growth and Income Funds

Analyst Recommendations for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.